Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Serrano

Showing results (91-100 of 223) with videos related to

Pageof 23
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2022
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort StudyJavier Martínez-Sanz, Sergio Serrano-Villar, Alfonso Muriel, et al.
Chemical Communications (Cambridge, England)|May 20, 2021
BINOLated aminostyryl BODIPYs: a workable organic molecular platform for NIR circularly polarized luminescenceJosué Jiménez, Carolina Díaz-Norambuena, Sergio Serrano, et al.
Frontiers in Immunology|November 25, 2022
Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2012
Authors' Reply: association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosisDulcenombre Gómez-Garre, Vicente Estrada, Adriana Ortega-Hernández, et al.
AIDS (London, England)|December 7, 2016
HIV, HPV, and microbiota: partners in crime?Sergio Serrano-Villar, Emilia Vásquez-Domínguez, José Antonio Pérez-Molina, et al.
Frontiers in Immunology|March 6, 2023
Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.
The Prostate|March 10, 2016
Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subsetSilvia Hernández, Alba Font-Tello, Núria Juanpere, et al.
Medicina Clinica|March 24, 2012
[Clinical factors and biomarkers associated with subclinical atherosclerosis in the human immunodeficiency virus infection]Sergio Serrano-Villar, Vicente Estrada, Dulcenombre Gómez-Garre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2012
Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosisDulcenombre Gómez-Garre, Vicente Estrada, Adriana Ortega-Hernández, et al.
Human Pathology|March 16, 2012
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancerNuria Juanpere, Laia Agell, Marta Lorenzo, et al.
Pageof 23

Showing results (91-100 of 223) with videos related to

Sort By:
Pageof 23
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 29, 2022
Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort StudyJavier Martínez-Sanz, Sergio Serrano-Villar, Alfonso Muriel, et al.
Chemical Communications (Cambridge, England)|May 20, 2021
BINOLated aminostyryl BODIPYs: a workable organic molecular platform for NIR circularly polarized luminescenceJosué Jiménez, Carolina Díaz-Norambuena, Sergio Serrano, et al.
Frontiers in Immunology|November 25, 2022
Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 25, 2012
Authors' Reply: association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosisDulcenombre Gómez-Garre, Vicente Estrada, Adriana Ortega-Hernández, et al.
AIDS (London, England)|December 7, 2016
HIV, HPV, and microbiota: partners in crime?Sergio Serrano-Villar, Emilia Vásquez-Domínguez, José Antonio Pérez-Molina, et al.
Frontiers in Immunology|March 6, 2023
Corrigendum: Translating the observed differences in interleukin-6 levels between some antiretroviral regimens into potential long-term risk of serious non-AIDS events: A modeling studySergio Serrano-Villar, Calvin Cohen, Jason V Baker, et al.
The Prostate|March 10, 2016
Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subsetSilvia Hernández, Alba Font-Tello, Núria Juanpere, et al.
Medicina Clinica|March 24, 2012
[Clinical factors and biomarkers associated with subclinical atherosclerosis in the human immunodeficiency virus infection]Sergio Serrano-Villar, Vicente Estrada, Dulcenombre Gómez-Garre, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 31, 2012
Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosisDulcenombre Gómez-Garre, Vicente Estrada, Adriana Ortega-Hernández, et al.
Human Pathology|March 16, 2012
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancerNuria Juanpere, Laia Agell, Marta Lorenzo, et al.
Pageof 23